<DOC>
	<DOCNO>NCT01135758</DOCNO>
	<brief_summary>Targeting glutamatergic system treat depression new promise strategy base study molecular , synaptic , neuronal level also result study conduct animal model first clinical study involve depressed patients.Ketamine propose novel approach induce rapid antidepressant response . In pilot project investigator aim introduce novel promising approach clinical practice . Besides assessment clinical efficacy , investigator put special emphasis assessment ketamine-associated effect brain function use fMRI cognitive testing .</brief_summary>
	<brief_title>Study Depression-Ketamine-Brain Function</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Men woman age 18 65 year diagnosis major depressive disorder without psychotic feature . Drugresistant depress patient ( define nonresponse two sufficiently long ( least 6 week ) drug trial maximal authorize tolerated dose ) Score 25 high MontgomeryAsberg Depression Rating Scale Stable psychotropic medication ( antidepressant , antipsychotic , mood stabilizer ) last 6 week prior inclusion . Legally competent subject agree comply requirement study authorize transmission relevant information competent physicians case clinically relevant previously unknown find MRI examination . Subjects comorbid substance abuse dependence 3 month prior inclusion , except nicotine consumption . Patients judge serious suicide risk ( score â‰¥ 4 item 10 MADRS ) . Patients DSMIV axis one diagnosis include bipolar disorder except anxiety disorder dominate clinical presentation . History antidepressant substanceinduced hypomania mania . History psychotic symptom . Patients contraindication administration ketamine , especially present diagnosis antecedent clinically relevant cardiovascular disorder ( clinically significant adequately treated hypertension , present previous diagnosis cardiovascular disorder stroke heart attack etc ) . Any MRI contraindication , especially metallic implant , pacemaker , etc . Pregnant woman , breastfeed woman , woman childbearing age without effective mean contraception . Treatment last 2 week thyroid hormone sympathicomimetic drug . Present past diagnosis eclampsia preeclampsia . Untreated insufficiently treat hyperthyroidism . Known hypersensitivity ketamine excipient ( benzethonium chloride ) . Present past diagnosis glaucoma , intracranial hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>depression , ketamine , fMRI</keyword>
</DOC>